drugset
drugset / Trial / NCT03915886

A Study of JNJ-64530440 in Healthy Japanese Male Participants

NCT03915886 ↗

Phase 1 Terminated 16 enrolled Janssen Pharmaceutical K.K. Janssen Research & Development, LLC · collab
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64530440 (JNJ-0440) in healthy Japanese adult male participants after single oral dose administration with ascending dose design.

Timeline

Start
2019-04-15
Primary completion
2019-07-17
Completion
2019-07-17

Outcome

Outcome not reported

Stopped (Business): “Stopped due to a strategic decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-0440 Unknown — Oral

Indications

No indication recorded.